Trading Halt
Filed with ASX · · 2 pages · English
On 6ix: 6ix.com/news/trading-halt-514
Trading in the securities of Island Pharmaceuticals Limited (‘ILA’) will be halted at the request of ILA, pending the release of an announcement by ILA. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Wednesday, 4 March 2026; or • the release of the announcement to the market. ILA’s request for a trading halt is
Island Pharmaceuticals Ltd on 6ix
Earlier from Island Pharmaceuticals
- Appendix 4D & Half-Year Financial Statements
- Response to ASX Query Letter
- $9m placement to advance US biodefence opportunity
- FDA confirms Galidesivir approval pathway
- Quarterly Appendix 4C and Activities Report
Later from Island Pharmaceuticals
- US Government collaboration for Galidesivir development
- Antiviral pipeline expansion through strategic collaboration
- Island Bolsters US Biodefence Readiness Ahead of Trials
- Island Adds Biodefence Leader as Filovirus Risks Escalate
- Island Advances Galidesivir GMP Manufacturing for Biodefence
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals